Abiopharma

🔍 Schwab-Pomerantz Carolyn (Director)

Company: SCHWAB CHARLES CORP (SCHW)

Report Date: 2026-05-05

Detailed Transactions and Holdings:

• Acquired 9,910 shares of Common Stock at $31.65 per share (Direct)
  Date: 2026-05-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 9,624.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 9,910 shares of Common Stock at $92.2916 per share (Direct)
  Date: 2026-05-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,396,458.66 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-05 | Code: H | nature_of_ownership: by Spouse as Trustee | shares_owned_after: 436,149.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-05 | Code: H | nature_of_ownership: by LLC | shares_owned_after: 2,798.00
• Sold 9,910 shares of Nonqualified Stock Option (right to buy) at $31.65 per share (Derivative)
  Date: 2026-05-05 | Code: M | Expires: 2026-11-01 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Reflects the contribution of the shares received upon exercise of the option to a revocable trust.
• F2: This transaction was executed in multiple trades at prices ranging from $92.23 to $92.38. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected.
• F3: This option was granted under the company's 2013 Stock Incentive Plan and vested in four annual installments beginning on the first anniversary of the grant date.